Clinical Trial Update: Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO) [Phase 4]

View source ↗

Summary

Phase 4 trial update examining evolocumab for in-stent restenosis and major adverse cardiovascular events.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• In-stent Restenosis
• Major Adverse Cardiovascular Events

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Lin Zhao | Conditions: In-stent Restenosis, Major Adverse Cardiovascular Events | Phase 4 | Status: UNKNOWN